Activin a stimulates AKR1C3 expression and growth in human prostate cancer

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5726-5734

  Hofland, Johannes ^a   Van Weerden, Wytske M ^a   Steenbergen, Jacobie ^a   Dits, Natasja F J ^a   Jenster, Guido ^a   De Jong, Frank H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; AKR1C3 ENZYME; ANDROSTENEDIONE; FOLLISTATIN; INHIBIN; INHIBIN BETA A; INHIBIN BETA B; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; METASTASIS FREE SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STEROIDOGENESIS; TESTOSTERONE SYNTHESIS; TUMOR XENOGRAFT; UPREGULATION;

3-HYDROXYSTEROID DEHYDROGENASES; ACTIVINS; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 84870231896     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-2065     Document Type: Article

References (40)

1. Damber JE, Aus G 2008 Prostate cancer. Lancet 371:1710-1721
2. Debes JD, Tindall DJ 2004 Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490
3. Schröder FH 2008 Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 53:1129-1137
4. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448
5. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; the Affirm Investigators 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 10.1056/NEJMoa1207506
8. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
9. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454
10. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825
11. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH, de Jong FH 2010 Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70:1256-1264
12. Massagué J 1987 The TGF-β family of growth and differentiation factors. Cell 49:437-438
13. Pangas SA, Woodruff TK 2000 Activin signal transduction pathways. Trends Endocrinol Metab 11:309-314
14. Martens JW, de Winter JP, Timmerman MA, McLuskey A, van Schaik RH, Themmen AP, de Jong FH 1997 Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells. Endocrinology 138:2928-2936
15. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W 2000 Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404:411-414
16. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H 1990 Activin-binding protein from rat ovary is follistatin. Science 247: 836-838
17. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY 2002 Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 227:75-87
18. Vänttinen T, Liu J, Kuulasmaa T, Kivinen P, Voutilainen R 2003 Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol 178:479-489
19. Hillier SG, Yong EL, Illingworth PJ, Baird DT, Schwall RH, Mason AJ 1991 Effect of recombinant activin on androgen synthesis in cultured human thecal cells. J Clin Endocrinol Metab 72:1206-1211
20. Mauduit C, Chauvin MA, de Peretti E, Morera AM, Benahmed M 1991 Effect of activin A on dehydroepiandrosterone and testosterone secretion by primary immature porcine Leydig cells. Biol Reprod 45:101-109
21. Hofland J, de Jong FH 2012 Inhibins and activins: Their roles in the adrenal gland and the development of adrenocortical tumors. Mol Cell Endocrinol 359:92-100
22. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, Risbridger GP 1999 Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140:5303-5309
23. van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, de Jong FH 2000 Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 82:112-117
24. Ying SY, Zhang Z, Huang G 1997 Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci 60:397-401
25. McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP 1997 Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 154:535-545
26. Carey JL, Sasur LM, Kawakubo H, Gupta V, Christian B, Bailey PM, Maheswaran S 2004 Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol 18:696-707
27. Zhang Z, Zhao Y, Batres Y, Lin MF, Ying SY 1997 Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 234:362-365
28. Kang HY, Huang HY, Hsieh CY, Li CF, Shyr CR, Tsai MY, Chang C, Chuang YC, Huang KE 2009 Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. J Bone Miner Res 24:1180-1193
29. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC 2007 The type III transforming growth factor-β receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67:1090-1098
30. Mellor SL, Richards MG, Pedersen JS, Robertson DM, Risbridger GP 1998 Loss of the expression and localization of inhibin α-subunit in high grade prostate cancer. J Clin Endocrinol Metab 83:969-975
31. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G 2006 Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 23:117-122
32. Chang GT, Steenbeek M, Schippers E, Blok LJ, van Weerden WM, van Alewijk DC, Eussen BH, van Steenbrugge GJ, Brinkmann AO 2001 A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. Eur J Cancer 37:2129-2134
33. Hofland J, van Nederveen FH, Timmerman MA, Korpershoek E, de Herder WW, Lenders JW, Verhofstad AA, de Krijger RR, de Jong FH 2007 Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry. Clin Endocrinol (Oxf) 66:335-340
34. Bui HN, Struys EA, Martens F, de Ronde W, Thienpont LM, Kenemans P, Verhoeven MO, Jakobs C, Dijstelbloem HM, Blankenstein MA 2010 Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy. Ann Clin Biochem 47:248-252
35. Thomas TZ, Wang H, Niclasen P, O'Bryan MK, Evans LW, Groome NP, Pedersen J, Risbridger GP 1997 Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 82:3851-3858
36. Auchus RJ 2004 The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 15:432-438
37. Luu-The V, Bélanger A, Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22:207-221
38. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
39. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748
40. Harrison CA, Gray PC, Vale WW, Robertson DM 2005 Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16:73-78